肾移植患者中使用奈玛特韦/利托那韦治疗COVID-19感染的管理与结局
该研究描述了渥太华医院肾移植项目中51例接受奈玛特韦/利托那韦治疗的COVID-19患者的管理与结局。通过暂停他克莫司并基于药物浓度调整剂量,他克莫司水平在治疗期间有波动,但未发生急性排斥或其他并发症,急性肾损伤不常见。数据受小样本量和短随访时间限制。
要点
- 肾移植患者使用奈玛特韦/利托那韦时,暂停他克莫司并基于药物浓度调整剂量可减少 supratherapeutic 水平。
- 治疗期间多数患者他克莫司水平低于治疗目标范围,但未发生急性排斥。
- 标准算法与简化算法在维持他克莫司水平方面效果相似。
核心结论
- 在开始奈玛特韦/利托那韦前一天暂停他克莫司并在完成治疗后3天恢复,导致 supratherapeutic 水平发生率低,但许多患者出现短期亚治疗水平。
- 急性肾损伤不常见。
- 数据受小样本量和短随访时间限制。
研究设计与样本
- 描述渥太华医院肾移植项目的临床经验,纳入2022年4月至6月期间接受奈玛特韦/利托那韦的患者,随访至治疗完成后30天。
- 共51例患者接受奈玛特韦/利托那韦。
主要发现
- 在暂停钙调神经磷酸酶抑制剂后7天及停用奈玛特韦/利托那韦后2天的第一次时间点,他克莫司水平在治疗目标范围内者17/44(39%),低于治疗范围者21/44(48%),高于治疗范围者6/44(14%)。
- 两周后,55%在治疗范围内,23%低于,23%高于。
- 标准算法与简化算法提供的他克莫司水平相似(中位数5.2 [4.0-6.2] µg/L 对比 4.8 [4.3-5.7] µg/L,P = 0.70)。
- 没有急性排斥或其他并发症。
临床怎么用
- 本研究中心的做法是:在开始奈玛特韦/利托那韦前一天暂停他克莫司,并在完成治疗后3天(第8天)根据前一天的药物水平恢复他克莫司。
- 最初30例患者根据第一周两次及之后按需进行的药物水平调整剂量,随后实施了减少钙调神经磷酸酶抑制剂水平监测频率的简化算法。
局限性
- 数据受小样本量限制。
- 数据受短随访时间限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nirmatrelvir/ritonavir has been shown to reduce the risk of coronavirus disease 2019 (COVID-19)-related complications in patients at high risk for severe COVID-19. However, clinical experience of nirmatrelvir/ritonavir in the transplant recipient population is scattered due to the complex management of drug-drug interactions with calcineurin inhibitors. We describe the clinical experience with nirmatrelvir/ritonavir at The Ottawa Hospital kidney transplant program. METHODS: Patients who received nirmatrelvir/ritonavir between April and June 2022 were included and followed up to 30 days after completion of treatment. Tacrolimus was withheld for 24 hours and resumed 72 hours after the last dose of nirmatrelvir/ritonavir (on day 8) on the basis of the drug level the day before. The first 30 patients had their dose adjusted according to drug levels performed twice in the first week and as needed thereafter. Subsequently, a simplified algorithm with less frequent calcineurin inhibitor-level monitoring was implemented. Outcomes, including tacrolimus-level changes, serum creatinine and AKI (defined as serum creatinine increase by 30%), and clinical outcomes were described globally and compared between algorithms. RESULTS: Fifty-one patients received nirmatrelvir/ritonavir. Tacrolimus levels drawn at the first time point, 7 days after withholding of calcineurin inhibitor, and 2 days after discontinuing nirmatrelvir/ritonavir were within the therapeutic target in 17/44 (39%), subtherapeutic in 21/44 (48%), and supratherapeutic in 6/44 (14%). Two weeks after, 55% were within the therapeutic range, 23% were below, and 23% were above it. The standard and simplified algorithms provided similar tacrolimus level (median 5.2 [4.0-6.2] µg/L versus 4.8 [4.3-5.7] µg/L, P = 0.70). There were no acute rejections or other complications. CONCLUSIONS: Withholding tacrolimus starting the day before initiation of nirmatrelvir/ritonavir with resumption 3 days after completion of therapy resulted in a low incidence of supratherapeutic levels but a short period of subtherapeutic levels for many patients. AKI was infrequent. The data are limited by the small sample size and short follow-up. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_07_10_CJN0000000000000186.mp3.
引用
- Giguère P, Deschenes MJ, Van Loon M, et al. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients. Clin J Am Soc Nephrol. 2023. PMID: 37099447. doi:10.2215/CJN.0000000000000186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。